Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
Abstract Bortezomib is a dipeptidyl boronic acid that selectively inhibits the ubiquitin proteasome pathway, which plays a role in the degradation of many intracellular proteins. It is the first-in-class selective and reversible inhibitor of the 26S proteasome, with antiproliferative and antitumor a...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2019-04-01
|
| Series: | Drugs in R&D |
| Online Access: | http://link.springer.com/article/10.1007/s40268-019-0269-9 |